SillaJen, Inc.

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
4,655 ^KRW	+1.97%		+7.63%	-22.80%

04-22	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
03-27	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index

September 18, 2023 at 05:00 am

Latest news about SillaJen, Inc.

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	04-22	CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	03-27	CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance	03-25	MT
SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index	18/09/23	CI
Switzerland's Basilea Pharmaceutica Secures $4 Million Milestone Payment for Oncology Asset	19/12/22	MT
SillaJen Resumes Trading on Kosdaq	13/10/22	MT
SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug	21/09/22	MT
Kosdaq Delists Biotechnology Company SillaJen	19/01/22	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	24/11/21	CI
SillaJen, Inc. announced that it has received KRW 40 billion in funding	30/08/21	CI
SillaJen, Inc. announced that it has received KRW 60 billion in funding from M2N Co.,Ltd	14/07/21	CI
SillaJen, Inc. announced that it expects to receive KRW 40 billion in funding	13/07/21	CI
SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd	30/05/21	CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc..	20/04/21	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index	21/09/20	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index	21/09/20	CI
SillaJen, Inc. announced that it has received KRW 20 billion in funding	23/04/20	CI
SillaJen, Inc. announced that it expects to receive KRW 20 billion in funding	22/04/20	CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC	02/08/19	CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)	06/06/19	CI
SillaJen, Inc. announced that it has received KRW 110 billion in funding	20/03/19	CI
SillaJen, Inc. announced that it expects to receive KRW 110 billion in funding	18/03/19	CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab	20/06/18	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/03/18	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/03/18	CI

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SILLAJEN, INC.	-22.80%	354M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B